Supplier
Massachusetts Eye and Ear Infirmary
Massachusetts Eye and Ear Infirmary was paid $68.24M by Medicaid between Jan 2018 and Dec 2024, across 208 billing codes. Its largest line is J9035, Injection, bevacizumab, 10 mg — 14% of everything it billed.
33Billing provider infoMASSACHUSETTS EYE AND EAR INFIRMARY
BOSTON, MA 02114
BOSTON, MA 02114
33aNPI1639101751assigned 07/07/2006
33bProvider typeEyewear Supplier
28Total paid$68.24M
24GClaims862,670
24DCodes billed208
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Eyewear Supplier providers in Massachusetts
Rank by total paid#1 of 27
Median peer was paid$60K
This provider vs. median1,137×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 116,829 | $7.81M | |
| 2019 | 114,057 | $9.06M | |
| 2020 | 87,030 | $7.59M | |
| 2021 | 127,481 | $10.55M | |
| 2022 | 143,349 | $11.79M | |
| 2023 | 143,449 | $10.65M | |
| 2024incomplete | 130,475 | $10.80M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9035 | Injection, bevacizumab, 10 mg | 14% | 4,942 | 4,677 | $9.29M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 10% | 57,377 | 53,367 | $6.84M |
| J0178 | Injection, aflibercept, 1 mg | 6.2% | 7,483 | 7,102 | $4.26M |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 6.2% | 6,849 | 6,444 | $4.21M |
| 67028 | Intravitreal injection of a pharmacologic agent | 4.6% | 23,587 | 22,234 | $3.12M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.5% | 28,042 | 26,078 | $3.10M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 4.0% | 2,129 | 2,102 | $2.70M |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 3.7% | 45,635 | 44,199 | $2.53M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 3.3% | 1,445 | 1,408 | $2.22M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.7% | 90,858 | 78,171 | $1.86M |
| 31575 | 2.5% | 10,483 | 9,897 | $1.74M | |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.4% | 17,406 | 16,455 | $1.66M |
196 more codes
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.2% | 13,906 | $1.47M |
| 31231 | 2.1% | 8,318 | $1.42M | |
| 99203 | Doctor's office visit, new patient (routine) | 1.8% | 10,109 | $1.20M |
| 92557 | 1.7% | 18,624 | $1.17M | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.6% | 2,507 | $1.11M |
| V5261 | Hearing aid, digital, binaural, bte | 1.4% | 1,278 | $952K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 8,939 | $868K |
| 99204 | Doctor's office visit, new patient (more involved) | 1.3% | 7,926 | $861K |
| 31237 | 1.2% | 1,028 | $832K | |
| 66982 | 1.2% | 1,443 | $790K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | 1.1% | 10,778 | $740K |
| V5160 | Dispensing fee, binaural | 1.1% | 1,446 | $724K |
| 99284 | Emergency room visit (serious) | 1.0% | 7,100 | $712K |
| 92567 | <1% | 20,343 | $653K | |
| 31579 | <1% | 1,184 | $552K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,892 | $552K |
| 64612 | <1% | 1,773 | $540K | |
| 67228 | <1% | 798 | $495K | |
| 92134 | <1% | 51,281 | $478K | |
| J2778 | Injection, ranibizumab, 0.1 mg | <1% | 1,028 | $448K |
| 42830 | <1% | 240 | $434K | |
| 76512 | <1% | 6,628 | $426K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 3,547 | $370K |
| 70491 | <1% | 3,316 | $358K | |
| 68761 | <1% | 2,396 | $341K | |
| 70543 | <1% | 1,387 | $315K | |
| 92235 | <1% | 2,161 | $252K | |
| 70486 | <1% | 2,638 | $250K | |
| 92083 | <1% | 25,318 | $236K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,927 | $233K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,456 | $222K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,710 | $218K |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 6,137 | $193K |
| 30520 | <1% | 221 | $186K | |
| 70480 | <1% | 2,043 | $182K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 3,180 | $181K |
| 92020 | <1% | 5,870 | $172K | |
| 92579 | <1% | 4,630 | $167K | |
| 69210 | <1% | 5,479 | $166K | |
| 92133 | <1% | 23,302 | $155K | |
| 92250 | <1% | 12,378 | $153K | |
| 74230 | <1% | 1,224 | $141K | |
| 92025 | <1% | 5,594 | $136K | |
| 92504 | <1% | 5,183 | $132K | |
| 30140 | <1% | 54 | $118K | |
| 99285 | Emergency room visit (most serious) | <1% | 1,219 | $115K |
| 76536 | <1% | 1,594 | $112K | |
| 92555 | <1% | 1,605 | $110K | |
| V5266 | Battery for use in hearing device | <1% | 2,913 | $104K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,549 | $95K |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 1,250 | $91K |
| 92587 | <1% | 657 | $90K | |
| 92593 | <1% | 2,848 | $85K | |
| 99205 | Prolong outpt/office vis | <1% | 766 | $75K |
| 67113 | <1% | 41 | $74K | |
| V5020 | Conformity evaluation | <1% | 1,679 | $73K |
| 92582 | <1% | 2,311 | $63K | |
| 66821 | <1% | 200 | $62K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 11,991 | $62K |
| 92585 | <1% | 227 | $59K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 24,936 | $57K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,739 | $50K |
| 92285 | <1% | 5,386 | $49K | |
| 76514 | <1% | 3,830 | $47K | |
| 92595 | <1% | 1,331 | $39K | |
| 92524 | <1% | 449 | $38K | |
| 87070 | <1% | 4,368 | $31K | |
| 92136 | <1% | 6,023 | $31K | |
| 67108 | <1% | 12 | $31K | |
| J2704 | Injection, propofol, 10 mg | <1% | 15,853 | $30K |
| 92226 | <1% | 3,549 | $27K | |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | <1% | 466 | $27K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 22,269 | $27K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,208 | $26K |
| V5011 | Fitting/orientation/checking of hearing aid | <1% | 311 | $26K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,259 | $26K |
| J3473 | Injection, hyaluronidase, recombinant, 1 usp unit | <1% | 648 | $26K |
| G0378 | Hospital observation service, per hour | <1% | 621 | $25K |
| 92537 | <1% | 249 | $25K | |
| 92591 | <1% | 501 | $21K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 3,315 | $21K |
| 65426 | <1% | 12 | $20K | |
| 92060 | <1% | 1,372 | $20K | |
| 66761 | <1% | 34 | $18K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 975 | $18K |
| 92201 | <1% | 2,549 | $17K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 17,248 | $16K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 268 | $13K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,881 | $13K |
| 69220 | <1% | 98 | $13K | |
| 87102 | <1% | 1,455 | $13K | |
| 92592 | <1% | 736 | $13K | |
| 88300 | <1% | 1,772 | $13K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 247 | $12K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,637 | $10K |
| 92604 | <1% | 416 | $10K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 890 | $10K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,577 | $10K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,202 | $9K |
| 92540 | <1% | 357 | $9K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 4,153 | $9K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 75 | $9K |
| 86480 | <1% | 285 | $9K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 9,715 | $9K |
| 87081 | <1% | 803 | $9K | |
| 92202 | <1% | 892 | $8K | |
| 87205 | <1% | 2,847 | $8K | |
| 66710 | <1% | 12 | $7K | |
| 92225 | <1% | 1,088 | $7K | |
| V5014 | Repair/modification of a hearing aid | <1% | 295 | $7K |
| 92652 | <1% | 104 | $6K | |
| 10005 | <1% | 15 | $5K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 174 | $5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 255 | $5K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,711 | $4K |
| 92594 | <1% | 174 | $4K | |
| 87077 | <1% | 712 | $4K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 4,417 | $4K |
| V2632 | Posterior chamber intraocular lens | <1% | 4,789 | $4K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 25 | $4K |
| 76516 | <1% | 174 | $4K | |
| 87186 | <1% | 596 | $4K | |
| V5241 | Dispensing fee, monaural hearing aid, any type | <1% | 14 | $3K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,356 | $3K |
| 92590 | <1% | 23 | $3K | |
| 86140 | <1% | 1,133 | $3K | |
| 92081 | <1% | 487 | $3K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 149 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,964 | $3K |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | <1% | 995 | $2K |
| 82164 | <1% | 315 | $2K | |
| 86617 | <1% | 261 | $2K | |
| 85652 | <1% | 1,651 | $2K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,455 | $2K |
| 87075 | <1% | 377 | $2K | |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | <1% | 1,847 | $2K |
| 92511 | <1% | 12 | $2K | |
| 88304 | <1% | 291 | $1K | |
| 92597 | <1% | 33 | $1K | |
| 92546 | <1% | 110 | $1K | |
| 86780 | <1% | 160 | $1K | |
| 85549 | <1% | 126 | $1K | |
| 86039 | <1% | 253 | $1K | |
| J1097 | Phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml | <1% | 40 | $1K |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 281 | $1K |
| 86592 | <1% | 436 | $1K | |
| 92015 | Determination of refractive state | <1% | 2,327 | $1K |
| ATP08 | <1% | 142 | $1K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 45 | $968.29 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 650 | $830.53 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 27 | $820.96 |
| 92626 | <1% | 12 | $648.89 | |
| 65222 | <1% | 14 | $605.25 | |
| 86481 | <1% | 14 | $529.14 | |
| 92553 | <1% | 13 | $484.80 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 38 | $363.45 |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,008 | $341.59 |
| 85027 | <1% | 96 | $327.75 | |
| V5010 | Assessment for hearing aid | <1% | 1,071 | $322.50 |
| V2630 | Anterior chamber intraocular lens | <1% | 1,049 | $300.10 |
| 87206 | <1% | 100 | $289.16 | |
| 71250 | <1% | 44 | $261.88 | |
| 88342 | <1% | 40 | $169.14 | |
| 67820 | <1% | 69 | $151.39 | |
| 87285 | <1% | 13 | $120.34 | |
| Q3014 | Telehealth originating site facility fee | <1% | 112 | $107.61 |
| 82962 | <1% | 790 | $102.82 | |
| 88313 | <1% | 40 | $93.23 | |
| 80053 | Comprehensive metabolic panel | <1% | 92 | $88.40 |
| A4217 | Sterile water/saline, 500 ml | <1% | 42 | $78.69 |
| 85610 | <1% | 27 | $77.14 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14 | $69.96 |
| A4263 | Permanent, long term, non-dissolvable lacrimal duct implant, each | <1% | 28 | $68.85 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 677 | $66.22 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 384 | $60.50 |
| 81025 | <1% | 13 | $57.24 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 21 | $51.74 |
| V2785 | Processing, preserving and transporting corneal tissue | <1% | 26 | $36.46 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 70 | $27.02 |
| 82565 | <1% | 13 | $5.29 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 78 | $1.60 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 575 | $0.00 |
| 80076 | 0% | 14 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 16 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 45 | $0.00 |
| J3260 | Injection, tobramycin sulfate, up to 80 mg | 0% | 20 | $0.00 |
| C9447 | Injection, phenylephrine and ketorolac, 4 ml vial | 0% | 12 | $0.00 |
| J9999 | Not otherwise classified, antineoplastic drugs | 0% | 41 | $0.00 |
| L8509 | Tracheo-esophageal voice prosthesis, inserted by a licensed health care provider, any type | 0% | 15 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 22 | $0.00 |
| A4262 | Temporary, absorbable lacrimal duct implant, each | 0% | 475 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 41 | $0.00 |
| G0268 | Removal of impacted cerumen (one or both ears) by physician on same date of service as audiologic function testing | 0% | 219 | $0.00 |
| 00142 | 0% | 13 | $0.00 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 12 | $0.00 |
| 92082 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCURRAN, EARL (DIRECTOR FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Massachusetts Eye and Ear Infirmary | Boston, MA | $449K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.